Pre-Activity Survey      Release Date: Monday, May 6, 2019     Expiration Date: Wednesday, May 6, 2020

Abuse-Deterrent Formulations
Opioids play an important role in the management of moderate-to-severe pain and the use of opioid medications has steadily increased over the past few decades. With the growing use of opioids, there has been a correlating increase in opioid abuse, diversion, and misuse. To combat opioid abuse, a multifaceted approach is needed that can include the use of abuse-deterrent formulations (ADFs). ADFs can employ various technologies, such as physical/chemical barriers to prevent crushing or extraction, as well as the use of an agonist/antagonist combination that neutralizes the opioid effect if manipulated. Though the use of ADFs can be an important component in ensuring the responsible use of opioids, the incorporation of ADFs into pain management decisions will require a thorough understanding of the available formulations, including the technologies utilized, dosing for optimal effectiveness, and safety considerations.

Opioid-Induced Constipation
Opioid-induced constipation (OIC) is one of the most common and troublesome adverse events associated with opioids, impacting the majority of patients being treated for chronic pain. In addition to the clinical consequences, OIC is also associated with diminished quality of life, compromised pain management, and increased use of healthcare resources. For many, laxatives remain the treatment of choice in preventing and managing OIC, but these agents are associated with significant limitations and risks. More recent advancements have led to the development of a more targeted approach that specifically counteracts the effects of opioids in the gastrointestinal tract. As the role of pharmacists in managing patients with chronic pain grows within the multidisciplinary team, it is imperative that pharmacists improve their competence in the prevention and treatment of OIC. This can include utilizing effective prevention strategies, recognizing the early signs of OIC, and selecting the optimal approach to treat OIC based on patient-specific factors.


This continuing pharmacy education activity is planned to meet the needs of pharmacists in a variety of practice settings, including large and small health systems, outpatient clinics, managed-care organizations, long-term care facilities, community, and academia. This activity would be especially beneficial for pharmacists, clinical specialists, managers, leaders, and educators who are interested in pain management, new drug therapies, and improving the care of patients with chronic pain.



This Online Presentation is based on a live pharmacy series throughout 2019. The activity is divided into 2 episodes and the following topics are covered:

Episode 1
Role of Abuse-Deterrent Formulations in Pain Management

  1. Why the need for abuse-deterrent formulations (ADFs)?
  2. Current and emerging technologies in opioid abuse deterrence
  3. How to incorporate ADFs into pain management decisions

Episode 2
Current Approaches to Address OIC

  1. Impact and burden of OIC
  2. Assessing patient risk for prevention
  3. Role of PAMORAs to target OIC

Note: If you have received credit for attending the live program by the same name, you are not eligible to apply for credit for this online version.


Upon completing this activity, participants will be able to:

  • Describe current and emerging abuse-deterrent technologies utilized in opioid medications
  • Evaluate the role of abuse-deterrent formulations of opioid medications when making pain management decisions
  • Discuss the impact of opioid-induced constipation (OIC) on a patient’s quality of life and overall well-being
  • Evaluate the use of peripherally-acting mu-opioid receptor antagonists (PAMORAs) in the prevention and management of OIC

Click here for additional resources.


Gregory L. Holmquist, PharmD, CPE
Certified Pain Educator
Pain Management / Palliative Care Pharmacist Specialist
Hospice / Palliative Care Consultant
Chronic Non-cancer Pain Consultant
LTC Elderly Pain Consultant
Private Pain Management Consultant
Palliative Care Strategies
Everett, WA




Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credits for participating in this activity.
ACPE UAN: 0473-9999-19-004-H01-P
Activity type: knowledge-based


For questions regarding the accreditation of this activity, please contact us at


Method of Participation and Instruction for Credit

  1. Review the entire CPE information including target audience, learning objectives, and disclosures.
  2. Review the activity in its entirety.
  3. Complete the Online Post Test, Evaluation, and Credit Application form
  4. Please note that to receive credit you must achieve a score of at least 80%.
  5. Credits will be uploaded to CPE Monitor within 4 weeks of activity completion and you will be able to access your credits from the profile you set up with NABP.

Disclosure of Conflicts of Interest

In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.

Gregory Holmquist, PharmD has relevant financial relationships with the following commercial interests:
Speakers Bureau: Daiichi-Sankyo, Inc.
Dr. Holmquist does not discuss off-label uses of any products.

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2019 Vemco MedEd. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support

This activity is supported by educational grants from Daiichi Sankyo, Inc. and Bausch Health

By clicking below, I acknowledge that I have read the entire CPE information.